Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2021 Financial Results on August 9, 2021
Rhea-AI Summary
Organogenesis Holdings Inc. (Nasdaq: ORGO) plans to release its second-quarter fiscal year 2021 financial results on August 9, after market close. The management will host a conference call at 5:00 p.m. ET on the same day to discuss the results, followed by a Q&A session. Interested participants can join the call via phone or through a live webcast available on the company's investor relations website. A replay will be accessible for two weeks post-call. Organogenesis specializes in regenerative medicine focused on advanced wound care and surgical solutions.
Positive
- Anticipated earnings report could reflect strong financial performance.
- Engagement with investors through an open Q&A session.
Negative
- None.
News Market Reaction – ORGO
In the trading session that priced this news, ORGO declined 2.27%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, August 9th.
Management will host a conference call at 5:00 p.m. Eastern Time on August 9th to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 1146847. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.
For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 1146847. The webcast will be archived at investors.organogenesis.com.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.